United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. Following the transaction, the director now directly owns 2,135 shares of the company’s stock, valued at $260,470. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Christopher Causey also recently made the following trade(s):

  • On Thursday, October 5th, Christopher Causey sold 580 shares of United Therapeutics Corporation stock. The shares were sold at an average price of $122.00, for a total value of $70,760.00.
  • On Thursday, September 7th, Christopher Causey sold 580 shares of United Therapeutics Corporation stock. The shares were sold at an average price of $134.48, for a total value of $77,998.40.

United Therapeutics Corporation (NASDAQ:UTHR) traded down $1.33 during trading hours on Friday, reaching $119.91. The company’s stock had a trading volume of 51,636 shares, compared to its average volume of 568,806. The company has a market capitalization of $5,334.40, a price-to-earnings ratio of 10.89 and a beta of 1.38. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.23 earnings per share. equities analysts anticipate that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/10/united-therapeutics-corporation-uthr-director-sells-70760-00-in-stock.html.

UTHR has been the subject of several recent research reports. Zacks Investment Research raised United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, October 26th. Cowen and Company reissued a “hold” rating and set a $129.00 price target on shares of United Therapeutics Corporation in a research report on Friday, October 27th. Finally, Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. United Therapeutics Corporation currently has a consensus rating of “Hold” and an average target price of $132.82.

A number of large investors have recently added to or reduced their stakes in the business. OppenheimerFunds Inc. increased its stake in shares of United Therapeutics Corporation by 24.8% during the first quarter. OppenheimerFunds Inc. now owns 2,881 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 573 shares during the period. Teachers Advisors LLC increased its stake in shares of United Therapeutics Corporation by 17.0% during the first quarter. Teachers Advisors LLC now owns 91,328 shares of the biotechnology company’s stock worth $12,364,000 after purchasing an additional 13,239 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of United Therapeutics Corporation by 4.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 95 shares during the period. Tudor Investment Corp ET AL increased its stake in shares of United Therapeutics Corporation by 4.7% during the first quarter. Tudor Investment Corp ET AL now owns 3,700 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 166 shares during the period. Finally, Credit Suisse AG increased its stake in shares of United Therapeutics Corporation by 32.9% during the first quarter. Credit Suisse AG now owns 109,463 shares of the biotechnology company’s stock worth $14,818,000 after purchasing an additional 27,101 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.